摘要
目的探讨结直肠癌组织中酰基辅酶A去饱和酶1(SCD-1)的表达及其临床意义。方法收集2014年12月至2017年12月手术切除的77对结直肠癌组织和癌旁组织,采用免疫组化SP法检测上述组织中SCD-1的表达情况,分析其表达差异及与临床病理特征的关系。结果 SCD-1主要表达于细胞浆和胞膜。在结直肠癌组织中SCD-1的阳性表达率为66.2%(51/77),高于癌旁正常组织的13.0%(10/77),差异有统计学意义(P<0.05)。SCD-1表达与性别、年龄、分化程度和部位均无关(P>0.05),而与肿瘤大小、浸润深度、淋巴结转移和TNM分期有关(P<0.05)。其中肿瘤较大(≥5 cm)、浸润较深(T_3+T_4)、淋巴结转移和分期较晚(Ⅲ+Ⅳ)的组织中SCD-1阳性表达率分别为80.6%(29/36)、72.9%(43/59)、78.6%(33/42)和78.0%(32/41),均高于肿瘤较小(<5 cm)、浸润较浅(T_1+T_2)、无淋巴结转移和分期较早(Ⅰ+Ⅱ)组织的53.7%(22/41)、44.4%(8/18)、51.4%(18/35)和52.8%(19/36),差异均有统计学意义(P<0.05)。结论 SCD-1蛋白高表达可能参与结直肠癌的发生、发展,SCD-1表达可能是肿瘤进展的潜在标志物。
Objective To investigate the expression and clinical significance of stearoy1?COA desaturase?1(SCD?1)in colo?rectal cancer tissues.Methods Seventy?seven pairs of colorectal cancer tissues and adjacent tissues were collected from December 2014 to December 2017.The expression of SCD?1 in the above tissues was detected by immunohistochemical SP method.The difference of SCD?1 expression and its relationship with clinicopathological features were analyzed.Results SCD?1 was mainly expressed in cyto?plasm and cell membrane by immunohistochemistry.The positive rate of SCD?1 expression was 66??2%(51/77)in colorectal cancer tissues,higher than 13??0%(10/77)of adjacent tissues with significant difference(P<0??05).The expression of SCD?1 was not relat?ed to gender,age,differentiation and tumor location(P>0??05),but associated with tumor size,depth of invasion,lymphnode metasta?sis and TNM staging(P<0??05).The positive expression rates of SCD?1 in tumors of≥5 cm in size,deep infiltration(T3+T4),lymph node metastasis and late staging(Ⅲ+Ⅳ)were 80??6%(29/36),72??9%(43/59),78??6%(33/42)and 78??0%(32/41),higher than 53??7%(22/41),44??4%(8/18),51??4%(18/35)and 52??8%(19/36)in corresponding tumors of small tumors(<5 cm),superficial infiltration(T1+T2),non?lymph node metastasis and early staging(Ⅰ+Ⅱ)with statistical significance(P<0??05).Con?clusion The elevated expression of SCD?1 may be involved in the development of colorectal cancer,and SCD?1 may be a potential marker for tumor progression.
作者
许镇
章礼久
贾犇黎
XU Zhen;ZHANG Lijiu;JIA Benli(Department of Gastroenterology, the Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China)
出处
《临床肿瘤学杂志》
CAS
北大核心
2019年第3期222-225,共4页
Chinese Clinical Oncology
